Aggressive pituitary tumours and pituitary carcinomas

Area of Science:

• Endocrinology
• Oncology
• Neurosurgery

Background:

• Anterior pituitary tumors are typically benign but can exhibit aggressive behavior, including invasion, rapid growth, and treatment resistance.
• In rare instances, these tumors metastasize, classifying them as pituitary carcinomas, with a significant time lag from initial diagnosis.

Purpose of the Study:

• To highlight the importance of regular monitoring for aggressive pituitary tumors using clinical and pathological markers.
• To discuss current therapeutic approaches and the potential of emerging personalized therapies for pituitary carcinomas.

Main Methods:

• Review of clinical and pathological markers (e.g., Ki67 index, mitotic count, p53 detection) for assessing tumor aggressiveness.
• Analysis of current treatment strategies, including surgery, radiotherapy, and medical therapies like temozolomide.
• Exploration of novel therapeutic avenues such as peptide receptor radionuclide therapy, angiogenesis-targeted therapy, and immunotherapy.

Main Results:

• Clinical and pathological markers indicate aggressiveness but cannot definitively predict malignancy without metastasis.
• Standard treatments offer limited efficacy for tumor progression, though they may control hypersecretion.
• Temozolomide shows effectiveness in only one-third of patients, underscoring the need for alternative treatments.

Conclusions:

• Regular monitoring is essential for patients with aggressive pituitary tumors due to the potential for progression to pituitary carcinoma.
• Current treatments are often insufficient, necessitating further research into tumor biology and the microenvironment.
• Personalized and emerging therapies hold promise for improving outcomes in patients with this severe condition.